- Anthropic has acquired stealth biotech AI startup Coefficient Bio for $400 million in stock, according to The Information and Eric Newcomer.
- Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, both former Genentech Prescient Design researchers specializing in computational drug discovery.
- The roughly 10-person Coefficient Bio team will join Anthropic’s health and life science division.
- The acquisition follows Anthropic’s October 2025 launch of Claude for Life Sciences, a specialized tool for scientific researchers.
What Happened
Anthropic has completed the purchase of Coefficient Bio, a stealth biotech AI startup, in a deal valued at $400 million in stock, as first reported by TechCrunch, citing reports from The Information and journalist Eric Newcomer. Sources close to the deal confirmed to TechCrunch that the transaction closed, though they declined to comment on the specific amount. The acquisition represents one of Anthropic’s largest known deals to date and signals a deepening commitment to applying large language models in the life sciences.
Coefficient Bio was founded approximately eight months ago by Samuel Stanton and Nathan C. Frey, both of whom previously worked in computational drug discovery at Genentech’s Prescient Design unit. The startup had been developing AI tools designed to accelerate drug discovery and other biological research workflows.
Why It Matters
The $400 million acquisition signals Anthropic’s aggressive expansion beyond its core large language model business into vertical applications for the life sciences. Anthropic launched Claude for Life Sciences in October 2025, a specialized tool designed to help scientific researchers accelerate discoveries through literature synthesis, experimental design assistance, and molecular analysis. The Coefficient Bio deal adds domain-specific talent and technology that could strengthen this product line substantially.
The acquisition also reflects a broader trend of AI labs using their highly valued stock as currency to acquire specialized teams rather than building expertise organically. At Anthropic’s current private market valuation, which has been climbing rapidly on secondary markets, a $400 million all-stock deal represents a relatively small dilution while securing a team with expertise that would take years to develop internally. The deal mirrors a pattern established by Google DeepMind’s parent Alphabet, which acquired Isomorphic Labs to pursue AI-driven drug discovery.
Technical Details
Coefficient Bio’s technical focus centered on using AI to make drug discovery and biological research more efficient. Both co-founders bring deep backgrounds in computational approaches to molecular design from Genentech’s Prescient Design, which has been one of the pharmaceutical industry’s most prominent computational drug discovery efforts. Stanton and Frey’s expertise spans machine learning approaches to protein engineering, small molecule design, and biological sequence modeling, areas where foundation models are increasingly being applied.
The team of approximately 10 people will be integrated into Anthropic’s health and life science team. This group has been building domain-specific capabilities on top of Claude‘s general-purpose architecture, including tools for automated literature review, experiment planning, and molecular property prediction. The Coefficient Bio team’s hands-on drug discovery experience complements the language model expertise already present at Anthropic.
The all-stock structure of the deal aligns the Coefficient Bio team’s financial incentives with Anthropic’s long-term performance, a common approach in talent-focused acquisitions where retaining key engineers and researchers is as important as acquiring technology. Given Anthropic’s surging secondary market valuation, the stock component may prove particularly valuable if the company continues its current trajectory.
Who’s Affected
Pharmaceutical companies and biotech firms that are current or potential users of Anthropic’s Claude for Life Sciences stand to benefit from the expanded capabilities the Coefficient Bio team may bring to the platform. Competitors in the AI-for-drug-discovery space, including Recursion Pharmaceuticals, Isomorphic Labs, and Insilico Medicine, face a strengthened competitor as Anthropic deepens its commitment to the sector. Genentech’s Prescient Design, which trained both co-founders, loses alumni to a company that could eventually compete with its internal computational biology capabilities.
What’s Next
Anthropic has not disclosed specific product plans for the Coefficient Bio team’s integration, though the acquisition is expected to enhance the Claude for Life Sciences offering with more specialized computational biology capabilities. The deal adds to Anthropic’s momentum in a week where the company has also seen surging demand for its shares on secondary markets and launched a political action committee. Whether the acquisition produces tangible improvements to Anthropic’s life sciences tools will depend on how effectively the small team’s domain expertise can be integrated with Anthropic’s broader model development and infrastructure.
